Source: Annual Congress 2008 - Mechanical ventilation and airway management
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
E. Ibrahim, A. Al-Gnady, A. Gad, M. Alsawi (Alexandria, Egypt). The study of the role of procalcitonin (PCT) in early detection of nosocomial infections in chest patients. Eur Respir J 2008; 32: Suppl. 52, 1923

Member's Comments

No comment yet.

Related content which might interest you: Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004 Procalcitonin (PCT) as a diagnostic tool in lower respiratory tract infections (LRTI) and TB Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001 Incidence of ventilator associated pneumonia (VAP) and assessment of serial estimation of procalcitonin levels as a prognostic marker in cases of VAP in a tertiary centre in India Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections Year: 2012 The role of procalcitonin in the differential diagnosis and in the response to treatment of lower respiratory tract infections Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia Source: Eur Respir J 2008; 32: 726-732 Year: 2008 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 The prognostic importance of plasma D-dimer levels in patients with community acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Serum procalcitonin (PCT-Q) as a diagnostic tool for bacterial lower respiratory tract infection among COPD patients with acute exacerbation Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Serum procalcitonine (PCT) as a marker of respiratory infection by pseudomonas aeruginosa (PA) in patients with COPD or bronchiectasis Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 The role of serum inflammatory markers in the detection of ventilation associated pneumonia (VAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Determining the prognostic value of procalcitonin in ICU patients who developed hospital acquired pneumonia and comparing with sencitive CRP Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009 Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Value of routine microbial investigation in low-risk patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 420s Year: 2002